CMPS (compasspathways.com) יחס שווי שוק לשווי בספרים
The biotech business of COMPASS Pathways plc (CMPS) relies on research centers in the US and UK to develop cutting-edge methods for treating depression. This chart illustrating the price evolution of the stock captured a value of 18.08. COMPASS Pathways plc (CMPS) aims for leadership in psychedelic medicine through its patent for the COMP360 molecule, although success depends on resolving FDA regulatory issues and the availability of funding for final-stage testing.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvouo2ve.rkk-7albim8&start=20220704&end=20261026&filename=GURU_Markets_-_CMPS_-_COMPASS-Pathways-plc_-_Market-Capitalization-to-Net-Assets "CMPS יחס שווי שוק לערך בספרים COMPASS Corp (04.07.2022 - 26.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור COMPASS Pathways PLC (CMPS)
This multiple compares the market value of the business to its net assets, reflecting the intensity of price volatility and the degree of capital protection via book value. By analyzing changes in the price-to-book multiple, investors assess market expectations for COMPASS Pathways plc (CMPS) innovations in synthetic psilocybin, where a high premium over assets is driven by the potential of a revolutionary treatment method for treatment-resistant depression.